stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Gross margin
Denali Therapeutics Inc.'s gross margin over the twelve months to 30 September 2026 was 98.7%, down 1.3 percentage points from fiscal 2023 (100.0%). Over the past ten years it has ranged from 0.00% (fiscal 2017) to 100.0% (fiscal 2023) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2023 | 100.0% | 0.00 |
| FY2022 | 100.0% | 0.00 |
| FY2021 | 100.0% | 0.00 |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 0.00 |
| FY2018 | 100.0% | 100.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 98.9% | 1.50 |
| Jun 2026 | 97.4% | 97.42 |
| Dec 2023 | 0.00% | (100.00) |
| Sep 2023 | 100.0% | 0.00 |
| 22 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| IDYA IDEAYA Biosciences, Inc. compare | 100.0% |
| VRDN Viridian Therapeutics, Inc. compare | 100.0% |
| DNLI Denali Therapeutics Inc. | 98.7% |
| TARS Tarsus Pharmaceuticals, Inc. compare | 93.2% |
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| DYN Dyne Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement